ANIMATION

Gleevec (imatinib) MOA

Share this article with:

Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling. The majority of gastrointestinal stromal tumor (GIST) cells have been found to present with overactive Kit signaling. Gleevec, or Glivec (imatinib mesylate) competitively binds to the ATP binding pocket of both active and inactive Kit, preventing downstream signaling. Kit inhibition by imatinib may induce both apoptosis and quiescence in KIT+ GIST cells.

Share It:
Contact XVIVO

Client


Novartis

The best things about working with XVIVO is probably the final product, that is never disappointing but, on the contrary, always beyond expectation. Our clients are happy and so are we. The second best thing is a very good production and revision process thru the web with a reliable schedule. It’s good not to be anxious because you know things will be done in due time (and well done).

Jean-Pascal Huvé, ScienceProd (Paris, France)